FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2950880342> ?p ?o ?g. }

• W2950880342 abstract "Background Pain is a priority for patients (pts) with psoriatic arthritis (PsA) and physicians. Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA. As pain is a multidimensional phenomenon, there is growing interest in understanding mechanisms of pain relief during treatment. Objectives To examine the potential role of inflammation in the effect of tofacitinib on pain in pts with PsA, using mediation modelling. Methods Data were from the Phase 3 OPAL Broaden (NCT01877668) and OPAL Beyond (NCT01882439) studies of pts with active PsA treated with tofacitinib 5 mg twice daily (BID) or placebo; pts were tumour necrosis factor inhibitor (TNFi)-naive or had previous inadequate response (IR) to ≥1 TNFi. All pts continued on a stable dose of a single conventional synthetic DMARD. Analyses used pooled and individual trial data (mean scores from Months 1, 2 and 3). Mediation modelling seeks to explain mechanisms underlying an observed relationship between independent and dependent variables via other explanatory variables (mediators). In this model, pain (100 mm visual analogue scale) was the designated dependent variable, treatment (tofacitinib 5 mg BID vs placebo) the independent variable and inflammation, measured by swollen joint count (SJC) and C-reactive protein (CRP), was a mediator. The primary model designated treatment effect on pain mediated via CRP/SJC as an indirect effect and treatment effect not attributable to CRP/SJC as a direct effect. Models were re-specified based on initial results; model invariance by population (TNFi-naive vs TNFi-IR pts) was assessed. Results In the pooled analysis (N=469), 25.9% (p 0.05), respectively. The treatment effect on pain not attributable to CRP/SJC (direct effect) was 74.1% (p Conclusion While inflammation, as assessed by CRP/SJC, was a significant mediator of the overall treatment effect on pain in tofacitinib-treated pts with PsA, the majority of the treatment effect was not attributable to CRP/SJC changes. When mediators were assessed individually, only CRP was a significant mediator in the pooled analysis. In the re-specified model, CRP-mediated effects differed in TNFi-naive vs TNFi-IR pts, but this was not statistically significant. These results suggest that CRP/SJC-associated inflammation only partially explains pain in PsA; other potential mediators need to be identified to better understand the treatment effect of tofacitinib on pain. Acknowledgement Study sponsored by Pfizer Inc. Medical writing support provided by AG McCluskey, PhD, of CMC Connect; funded by Pfizer Inc. Disclosure of Interests Peter C. Taylor Grant/research support from: Celgene, Galapagos, Eli Lilly, UCB, Consultant for: AbbVie, Galapagos, Gilead, Eli Lilly, Pfizer Inc, Philip J Mease Grant/research support from: AbbVie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, SUN and UCB, Consultant for: AbbVie, Amgen, BMS, Galapagos, Gilead Sciences, Inc., Janssen, Lilly, Novartis, Pfizer, SUN and UCB, Speakers bureau: AbbVie, Amgen, BMS, Celgene, Genentech, Janssen, Lilly, Novartis, Pfizer and UCB, Andrew G Bushmakin Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Joseph C Cappelleri Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Roy Fleischmann Grant/research support from: AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Celtrion, Genentech, GSK, Janssen, Lilly, Novartis, Pfizer Inc, Sanofi-Aventis, UCB, Consultant for: AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Celtrion, Genentech, GSK, Janssen, Lilly, Novartis, Pfizer Inc, Sanofi-Aventis, UCB, Lara Fallon Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, John Woolcott Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Alexis Ogdie Grant/research support from: (To my university) Novartis, Pfizer, Grant/research support from: Novartis, Pfizer, Grant/research support from: Novartis, Pfizer, Grant/research support from: Novartis, Pfizer, Consultant for: AbbVie, Bristol-Myers Squibb, Celgene, Corrona, Eli Lilly and Company, Novartis, Pfizer, and Takeda, Consultant for: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Corrona, Eli Lilly, Novartis, Pfizer Inc, Takeda, Consultant for: Abbvie, Amgen, BMS, Celgene, Corrona, Lilly, Novartis, Pfizer, Takeda, Consultant for: Abbvie, Amgen, BMS, Celgene, Corrona, Lilly, Novartis, Pfizer, Takeda, Valderilio F Azevedo Grant/research support from: AbbVie, GSK, Janssen, Merck Serono, Novartis, Pfizer Inc, UCB, Consultant for: AbbVie, GSK, Janssen, Merck Serono, Novartis, Pfizer Inc, UCB, Kurt de Vlam Consultant for: Pfizer Inc, Consultant for: Johnson & Johnson" @default.
• W2950880342 created "2019-06-27" @default.
• W2950880342 creator A5009475149 @default.
• W2950880342 creator A5014427334 @default.
• W2950880342 creator A5017740190 @default.
• W2950880342 creator A5031955903 @default.
• W2950880342 creator A5046261111 @default.
• W2950880342 creator A5049261212 @default.
• W2950880342 creator A5081778211 @default.
• W2950880342 creator A5087471106 @default.
• W2950880342 creator A5090182951 @default.
• W2950880342 creator A5091669022 @default.
• W2950880342 date "2019-06-01" @default.
• W2950880342 modified "2023-10-17" @default.
• W2950880342 title "FRI0462 UNDERSTANDING MEDIATORS OF PAIN REDUCTION IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH TOFACITINIB: ROLE OF INFLAMMATION" @default.
• W2950880342 doi "https://doi.org/10.1136/annrheumdis-2019-eular.1921" @default.
• W2950880342 hasPublicationYear "2019" @default.
• W2950880342 type Work @default.
• W2950880342 sameAs 2950880342 @default.
• W2950880342 citedByCount "0" @default.
• W2950880342 crossrefType "proceedings-article" @default.
• W2950880342 hasAuthorship W2950880342A5009475149 @default.
• W2950880342 hasAuthorship W2950880342A5014427334 @default.
• W2950880342 hasAuthorship W2950880342A5017740190 @default.
• W2950880342 hasAuthorship W2950880342A5031955903 @default.
• W2950880342 hasAuthorship W2950880342A5046261111 @default.
• W2950880342 hasAuthorship W2950880342A5049261212 @default.
• W2950880342 hasAuthorship W2950880342A5081778211 @default.
• W2950880342 hasAuthorship W2950880342A5087471106 @default.
• W2950880342 hasAuthorship W2950880342A5090182951 @default.
• W2950880342 hasAuthorship W2950880342A5091669022 @default.
• W2950880342 hasBestOaLocation W29508803421 @default.
• W2950880342 hasConcept C126322002 @default.
• W2950880342 hasConcept C142724271 @default.
• W2950880342 hasConcept C16005928 @default.
• W2950880342 hasConcept C204787440 @default.
• W2950880342 hasConcept C27081682 @default.
• W2950880342 hasConcept C2776233030 @default.
• W2950880342 hasConcept C2776260265 @default.
• W2950880342 hasConcept C2777077863 @default.
• W2950880342 hasConcept C2777575956 @default.
• W2950880342 hasConcept C2778886723 @default.
• W2950880342 hasConcept C2780564577 @default.
• W2950880342 hasConcept C2908647359 @default.
• W2950880342 hasConcept C71924100 @default.
• W2950880342 hasConcept C99454951 @default.
• W2950880342 hasConceptScore W2950880342C126322002 @default.
• W2950880342 hasConceptScore W2950880342C142724271 @default.
• W2950880342 hasConceptScore W2950880342C16005928 @default.
• W2950880342 hasConceptScore W2950880342C204787440 @default.
• W2950880342 hasConceptScore W2950880342C27081682 @default.
• W2950880342 hasConceptScore W2950880342C2776233030 @default.
• W2950880342 hasConceptScore W2950880342C2776260265 @default.
• W2950880342 hasConceptScore W2950880342C2777077863 @default.
• W2950880342 hasConceptScore W2950880342C2777575956 @default.
• W2950880342 hasConceptScore W2950880342C2778886723 @default.
• W2950880342 hasConceptScore W2950880342C2780564577 @default.
• W2950880342 hasConceptScore W2950880342C2908647359 @default.
• W2950880342 hasConceptScore W2950880342C71924100 @default.
• W2950880342 hasConceptScore W2950880342C99454951 @default.
• W2950880342 hasLocation W29508803421 @default.
• W2950880342 hasOpenAccess W2950880342 @default.
• W2950880342 hasPrimaryLocation W29508803421 @default.
• W2950880342 hasRelatedWork W2312580319 @default.
• W2950880342 hasRelatedWork W2737739855 @default.
• W2950880342 hasRelatedWork W2749276380 @default.
• W2950880342 hasRelatedWork W2751178115 @default.
• W2950880342 hasRelatedWork W2754141291 @default.
• W2950880342 hasRelatedWork W2754241130 @default.
• W2950880342 hasRelatedWork W2755195810 @default.
• W2950880342 hasRelatedWork W2808240072 @default.
• W2950880342 hasRelatedWork W2896812857 @default.
• W2950880342 hasRelatedWork W2901200582 @default.
• W2950880342 hasRelatedWork W2910355860 @default.
• W2950880342 hasRelatedWork W2951311906 @default.
• W2950880342 hasRelatedWork W2951754602 @default.
• W2950880342 hasRelatedWork W3033095461 @default.
• W2950880342 hasRelatedWork W3034117249 @default.
• W2950880342 hasRelatedWork W3045428151 @default.
• W2950880342 hasRelatedWork W3095584460 @default.
• W2950880342 hasRelatedWork W3122258052 @default.
• W2950880342 hasRelatedWork W3123452764 @default.
• W2950880342 hasRelatedWork W3165731211 @default.
• W2950880342 isParatext "false" @default.
• W2950880342 isRetracted "false" @default.
• W2950880342 magId "2950880342" @default.
• W2950880342 workType "article" @default.